Recent Advances in the Treatment of Chronic GVHD: ASH 2024 - Episode 7

FDA-Approved Therapies for Chronic GVHD

Panelists review the data supporting the use of currently FDA-approved therapies for the management of chronic graft-versusvs-host disease (cGVHD), focusing on efficacy, safety, and real-world outcomes in clinical practice.

EP. 1: Understanding Graft-VS-Host Disease (GVHD) Basics
EP. 2: Early Diagnosis and Intervention in GVHD Part 1
EP. 3: Early Diagnosis and Intervention in GVHD Part 2
EP. 4: Managing Skin Manifestations and Organ Involvement in GVHD
EP. 5: Treatment Decision-Making in Chronic GVHD
EP. 6: NCCN Guidelines and Clinical Updates in Chronic GVHD
Now Viewing
EP. 7: FDA-Approved Therapies for Chronic GVHD
EP. 8: Challenges, Limitations, and Treatment Sequencing in Chronic GVHD
EP. 9: Future Perspectives and Key Takeaways

Video content above is prompted by the following:

Now’s let’s review data supporting the use of currently approved FDA therapies for the management of chronic cGVvHD.